Cargando…
Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma
Tumor-induced osteomalacia is a rare acquired metabolic bone disorder characterized by isolated renal phosphate wasting due to abnormal tumor production of fibroblast growth factor 23. We report the case of a 59 year old woman referred to our department with a long history of progressive diffuse mus...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107201/ https://www.ncbi.nlm.nih.gov/pubmed/27709474 http://dx.doi.org/10.1007/s12020-016-1092-5 |
_version_ | 1782467174420447232 |
---|---|
author | Slot-Steenks, Mathilde M. Bruins Hamdy, Neveen A.T. van de Sande, Michiel A.J. Vriens, Dennis Cleven, Arjen H.G. Appelman-Dijkstra, Natasha M. |
author_facet | Slot-Steenks, Mathilde M. Bruins Hamdy, Neveen A.T. van de Sande, Michiel A.J. Vriens, Dennis Cleven, Arjen H.G. Appelman-Dijkstra, Natasha M. |
author_sort | Slot-Steenks, Mathilde M. Bruins |
collection | PubMed |
description | Tumor-induced osteomalacia is a rare acquired metabolic bone disorder characterized by isolated renal phosphate wasting due to abnormal tumor production of fibroblast growth factor 23. We report the case of a 59 year old woman referred to our department with a long history of progressive diffuse muscle weakness and pain, generalized bone pains and multiple insufficiency fractures of heels, ankles and hips due to a hypophosphatemic osteomalacia. A fibroblast growth factor 23-producing phosphaturic mesenchymal tumor localized in the left quadriceps femoris muscle was identified 7 years after onset of symptoms. Excision of the tumor resulted in normalization of serum phosphate and fibroblast growth factor 23 levels and in complete resolution of the clinical picture with disappearance of all musculoskeletal symptoms. This case illustrates the diagnostic difficulties in establishing a diagnosis tumor-induced osteomalacia and in identifying the responsible tumor. Our case underscores the clinical need to investigate all patients with persistent musculoskeletal symptoms for hypophosphatemia. A systematic approach is of pivotal importance because early recognition and treatment of the metabolic abnormality can prevent deleterious effects of osteomalacia on the skeleton. |
format | Online Article Text |
id | pubmed-5107201 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-51072012016-11-29 Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma Slot-Steenks, Mathilde M. Bruins Hamdy, Neveen A.T. van de Sande, Michiel A.J. Vriens, Dennis Cleven, Arjen H.G. Appelman-Dijkstra, Natasha M. Endocrine Clinical Management of Endocrine Diseases Tumor-induced osteomalacia is a rare acquired metabolic bone disorder characterized by isolated renal phosphate wasting due to abnormal tumor production of fibroblast growth factor 23. We report the case of a 59 year old woman referred to our department with a long history of progressive diffuse muscle weakness and pain, generalized bone pains and multiple insufficiency fractures of heels, ankles and hips due to a hypophosphatemic osteomalacia. A fibroblast growth factor 23-producing phosphaturic mesenchymal tumor localized in the left quadriceps femoris muscle was identified 7 years after onset of symptoms. Excision of the tumor resulted in normalization of serum phosphate and fibroblast growth factor 23 levels and in complete resolution of the clinical picture with disappearance of all musculoskeletal symptoms. This case illustrates the diagnostic difficulties in establishing a diagnosis tumor-induced osteomalacia and in identifying the responsible tumor. Our case underscores the clinical need to investigate all patients with persistent musculoskeletal symptoms for hypophosphatemia. A systematic approach is of pivotal importance because early recognition and treatment of the metabolic abnormality can prevent deleterious effects of osteomalacia on the skeleton. Springer US 2016-10-05 2016 /pmc/articles/PMC5107201/ /pubmed/27709474 http://dx.doi.org/10.1007/s12020-016-1092-5 Text en © The Author(s) 2016 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Clinical Management of Endocrine Diseases Slot-Steenks, Mathilde M. Bruins Hamdy, Neveen A.T. van de Sande, Michiel A.J. Vriens, Dennis Cleven, Arjen H.G. Appelman-Dijkstra, Natasha M. Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma |
title | Identifying the culprit lesion in tumor induced hypophosphatemia,
the solution of a clinical enigma |
title_full | Identifying the culprit lesion in tumor induced hypophosphatemia,
the solution of a clinical enigma |
title_fullStr | Identifying the culprit lesion in tumor induced hypophosphatemia,
the solution of a clinical enigma |
title_full_unstemmed | Identifying the culprit lesion in tumor induced hypophosphatemia,
the solution of a clinical enigma |
title_short | Identifying the culprit lesion in tumor induced hypophosphatemia,
the solution of a clinical enigma |
title_sort | identifying the culprit lesion in tumor induced hypophosphatemia,
the solution of a clinical enigma |
topic | Clinical Management of Endocrine Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107201/ https://www.ncbi.nlm.nih.gov/pubmed/27709474 http://dx.doi.org/10.1007/s12020-016-1092-5 |
work_keys_str_mv | AT slotsteenksmathildembruins identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma AT hamdyneveenat identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma AT vandesandemichielaj identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma AT vriensdennis identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma AT clevenarjenhg identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma AT appelmandijkstranatasham identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma |